Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Novel adjunctive therapies for the treatment of tuberculosisDetermination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.Six months therapy for tuberculous meningitisRecent Developments and Future Opportunities in the Treatment of Tuberculosis in ChildrenPediatric anthrax clinical managementIn silico evaluation and exploration of antibiotic tuberculosis treatment regimensDefining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: Epidemiology and clinical management.Recent advances in tuberculosis: New drugs and treatment regimens.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Initial Antituberculous Regimen with Better Drug Penetration into Cerebrospinal Fluid Reduces Mortality in HIV Infected Patients with Tuberculous Meningitis: Data from an HIV Observational Cohort Study.Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weightingDrug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome.Therapy duration and long-term outcomes in extra-pulmonary tuberculosis.Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Clinical management of concurrent diabetes and tuberculosis and the implications for patient servicesDiagnosis and treatment of extrapulmonary tuberculosisNovel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for childrenA hypothetical astrocyte-microglia lactate shuttle derived from a (1)H NMR metabolomics analysis of cerebrospinal fluid from a cohort of South African children with tuberculous meningitis.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients.Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study.Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia.Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines.Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive patients in Indonesia.Drug-resistant tuberculous meningitis.Bacterial meningitis: new therapeutic approaches.Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.Tuberculous meningitis: advances in diagnosis and treatment.Bacterial meningitis: an update of new treatment options.Emerging drugs and alternative possibilities in the treatment of tuberculosis.
P2860
Q24202081-BFE6D588-E540-4C23-87C1-1A994B8A9D81Q26829957-48BA15E8-57D2-483B-B70F-D9DE62957306Q27324299-C0EDE777-06DD-40DC-9F5F-FA6751AF834DQ28074247-6E9F5C5D-550C-47BE-A9E7-B2E38BB5BF77Q28085210-772AB4D7-482B-49E5-AB42-9D0715E9B3CAQ28397091-76372076-5C2A-4A0F-80D5-6E91B927AEA1Q28607283-31F89CC9-3D23-4E89-94FE-808E1A7CE967Q30234699-F69505FD-FF55-4335-B894-E05F213EAFC6Q30360811-4EB71E7F-5DE7-46B3-B387-C26A65A5731EQ30411703-1C963CC4-2CDD-4463-A843-7E07C04C906DQ30664628-CD8B7704-CA1A-42C1-A3BD-CFA88203FE0EQ31102969-3DB90040-6707-47B3-ACA0-ADD91DBFCB34Q33801345-5255C2AB-04CB-420F-A4B1-753AAA3836A3Q34137755-FF0C77A4-6DEF-4346-83FF-E9ACF23C6066Q34488659-E87DFB05-13D1-4015-9199-A47BF8034104Q35104725-9E640C73-DE84-47C0-BADD-8BF5511B6E45Q35169089-759846B1-6379-433C-8FDC-A0296FC5DAE1Q35197257-28EB21DC-B0E8-451A-861F-ACCE1BE66352Q35240921-FCB5892B-51A9-43E1-86FE-175036CAC4F6Q35307259-03C2248B-9D7F-4748-B665-DC39C38A5AE3Q35607718-367F29B2-F0AF-49CC-8401-495FF1224748Q35742101-FB8F210D-4014-492B-994C-254CCD4A2C8FQ35763118-A5FE4013-006E-4C7B-AD01-A3D969EE2C0CQ35867681-00D690A9-0C45-4183-9466-8C3D37E223A3Q35963971-8D8CD6B1-0032-478F-B949-BA9C264B408DQ35978007-649FA561-39D0-4C3F-8D68-88103DF989C9Q36166714-E277429A-9DEA-428F-A0E1-BE488E6C523EQ36273077-B941F34A-CF7F-4C85-AB2D-A9FD62DDA42DQ36349886-51A779A8-33CB-4F3B-A435-E8C92123605CQ36644907-BBD9AAC4-D4D4-4833-8CC4-8498C2E7E737Q36979305-F60B0E5B-20A3-43D0-A91F-63D3845826DEQ37162418-92258E52-81C5-49CE-AAE8-67F7F003949DQ37339290-478DD7B6-D246-4DDE-ADB0-A5A36B995CCDQ37530766-CA0DC284-2567-47F4-899A-0593A33C836CQ38113260-FAD4831F-D92C-4B14-9541-EA0AFAB118ECQ38145360-2B5381BC-EA84-4EF7-ABCF-0226603ED447Q38244769-AC08420F-F0EA-4EBF-A060-D283C1840938Q38360615-CC189937-EA27-461D-B8A3-A47ECD76A01DQ38570487-1B847D67-73F4-4D24-97EC-E49B84F1C071Q38724073-1E4B801A-A15F-4390-9B18-9E9C6157442A
P2860
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Intensified regimen containing ...... ised controlled phase 2 trial.
@ast
Intensified regimen containing ...... ised controlled phase 2 trial.
@en
Intensified regimen containing ...... ised controlled phase 2 trial.
@nl
type
label
Intensified regimen containing ...... ised controlled phase 2 trial.
@ast
Intensified regimen containing ...... ised controlled phase 2 trial.
@en
Intensified regimen containing ...... ised controlled phase 2 trial.
@nl
prefLabel
Intensified regimen containing ...... ised controlled phase 2 trial.
@ast
Intensified regimen containing ...... ised controlled phase 2 trial.
@en
Intensified regimen containing ...... ised controlled phase 2 trial.
@nl
P2093
P1476
Intensified regimen containing ...... ised controlled phase 2 trial.
@en
P2093
A Rizal Ganiem
Andre J van der Ven
George Borm
Lika Apriani
Rob E Aarnoutse
Rovina Ruslami
Tri Hanggono Achmad
P356
10.1016/S1473-3099(12)70264-5
P577
2012-10-25T00:00:00Z